This review assessed gastroprotective strategies for people taking non-steroidal anti-inflammatory drugs (NSAIDs). The authors concluded that misoprostol and cyclo-oxygenase-2 (COX-2) specific and selective NSAIDs significantly reduce symptomatic ulcers, while misoprostol and probably COX-2 specifics significantly reduce serious gastrointestinal complications, although the quality of the data was poor. This was a well-conducted review and the authors' conclusions appear reliable.
Data extraction
Two reviewers independently extracted the data and resolved any disagreements through discussion. For each comparison, data were on the number of people with each outcome were extracted for the longest follow-up point and used to derive a relative risk (RR).
Methods of synthesis
How were the studies combined?
The results from the individual studies were combined using a random-effects meta-analysis, where appropriate. A pooled RR with 95% confidence intervals (CIs) was calculated separately for each gastroprotective strategy for each outcome of interest. The number-needed-to-treat to prevent one symptomatic ulcer was calculated where data permitted. Publication bias was assessed using funnel plots and Egger's and Begg's tests.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the Cochran test (with a significance level of P<0.1) and by visual assessment of forest plots. A random-effects meta-regression was used to examine the influence on symptomatic ulcers of length of follow-up, mean age of the participants, baseline gastrointestinal status and a number of initial risk factors for gastrointestinal harms. A sensitivity analysis was performed by omitting studies with a 'high' risk of bias, treatment arms with higher than recommended doses of NSAID or gastroprotective agent, and naproxen treatment arms (for deaths and serious cardiovascular and renal events).
Results of the review
One hundred and twelve RCTs (n=76,666) were included.
Five studies were considered to be at low risk for bias. Methodological flaws of the studies included lack of systematic reporting of important outcomes, overlapping of some outcomes, and lack of reporting allocation concealment and blinding of the outcomes assessment. The authors stated that few authors provided, or were able to provide, additional data when contacted and that few studies did not receive funding from pharmaceutical companies.
Non-selective NSAID plus H2 receptor antagonists versus placebo plus non-selective NSAID: 15 RCTs (2,621 patients) were identified, none of which were judged to be at low risk of bias. There were insufficient data to adequately compare H2 receptor antagonists with placebo on any of the primary outcomes. H2 receptor antagonists significantly reduced endoscopic ulcers compared with placebo (RR 0.55, 95% CI: 0.4, 0.7).
Non-selective NSAID plus PPIs versus placebo plus non-selective NSAID: 6 RCTs (1,358 patients) were identified, one of which was judged to be at low risk of bias. There were insufficient data to compare PPIs with placebo in terms of serious gastrointestinal complications, serious cardiovascular or renal conditions, quality of life, or death. The significant reduction in symptomatic ulcers with PPI versus placebo (RR 0.09, 95% CI: 0.0, 0.5) was lost on sensitivity analysis. The significant reduction in endoscopic ulcers with PPI versus placebo (RR 0.37, 95% CI: 0.3, 0.5) remained on sensitivity analysis.
Non-selective NSAID plus misoprostol versus placebo plus non-selective NSAID: 23 RCTs (16,945 patients) were identified, one of which was judged to be at low risk of bias. Misoprostol significantly reduced serious gastrointestinal complications (RR 0.57, 95% CI: 0.4, 0.9), symptomatic ulcers (RR 0.36, 95% CI: 0.2, 0.7) and endoscopic ulcers (RR 0.33, 95% CI: 0.3, 0.4). No statistically significant heterogeneity was detected and the results were stable to sensitivity analysis.
